KT-621 Week 16 EASI-75 advantage over placebo
Above 40.0 pp at 30%, Above 25.0 pp at 96% and Above 20.0 pp at 96% on Kalshi as of 01:38 UTC on 21 Nov 2026.
If the difference between KT-621’s and placebo’s Week 16 EASI-75 response rates in the Phase 2b BROADEN2 trial (NCT07217015), as reported in the Initial Disclosure on or before Dec 31, 2026 at 11:59:59 PM ET, is above 20.0 percentage points, then the market resolves to Yes.
These are the three most traded over the last day of the five separate markets in this Kalshi event. Trading on Kalshi is due to end on 1 January 2027 and Kalshi-reported volume is 6.49k contracts and all of it came in the last day. This event is tracked by pdata.world next to twenty-four related events on Kalshi, Manifold, Polymarket and Predict including the Polymarket event titled FDA approves Retatrutide this year. Price history for each of the five markets of this Kalshi finance event is available from pdata.world as JSON and through its MCP server.